Clinical Trials Browser

Phase 1/2 × INDUSTRY × Waldenstrom Macroglobulinemia × Clear all

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07249905 2026-03-03

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

Phase 1/2 Recruiting

180 enrolled

LymphoidSarcoma

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Dendritic Cell Sarcoma, Interdigitating

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Phase 1/2 Completed

803 enrolled 2 FDA

LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT02362035 2025-12-11

KEYNOTE145

Phase 1/2 Completed

161 enrolled 29 charts

LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04172246 2025-11-21

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Phase 1/2 Completed

55 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03162536 2025-09-08

ARQ 531-101

Phase 1/2 Active not recruiting

190 enrolled

LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT05294731 2025-04-20

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Phase 1/2 Recruiting

146 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01647971 2022-11-21

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

39 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01416428 2022-11-08

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Phase 1/2 Terminated

210 enrolled

LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT03037645 2020-10-19

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Phase 1/2 Terminated

39 enrolled

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02092909 2019-09-10

8400-401

Phase 1/2 Terminated

31 enrolled 18 charts

Lymphoid

Waldenstrom Macroglobulinemia

NCT02363439 2018-01-09

Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401

Phase 1/2 Completed

5 enrolled 4 charts

Lymphoid

Waldenstrom Macroglobulinemia

NCT02981745 2017-07-19

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Phase 1/2 Unknown

200 enrolled

LymphoidOther hematologic neoplasm

Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

CaDAnCe-101

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

KEYNOTE145

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

ARQ 531-101

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

8400-401

Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia